Ahn Jaehyun, Kim Joonseok, Shin Christopher, Ahn Stephen
College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Department of Neurosurgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpodae-ro, Seocho-gu, Seoul, 06591, South Korea.
Acta Neurochir (Wien). 2025 Jul 10;167(1):188. doi: 10.1007/s00701-025-06579-4.
The association between anthropometric measures including BMI, height and cancer has been widely discussed. However, the role of these in the development and prognosis of glioma remains controversial. We aimed to study these relationships.
We followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Papers reporting relationship between anthropometric measures and the risk of glioma, both incidence and survival, were considered relevant. Those published until January 31, 2024, were selected from PubMed, EMBASE, and the Cochrane Library. Studies were evaluated according to the modified Newcastle Ottawa Scale. Hazard ratios, relative risks, and 95% confidence intervals were pooled and synthesized using a random effects model.
Among 940 screened articles, 23 were selected. Taller height was significantly associated with an increased risk of both glioma (HR per 10 cm, 1.19; CI, 1.16 to 1.23) and glioblastoma (HR per 10 cm, 1.25; CI, 1.18 to 1.31). Higher BMI was positively correlated with an increased risk of glioma, both in categorical (RR, 1.08; CI, 1.03 to 1.12) and continuous measures (HR per 5 kg/m, 1.01; CI, 1.00 to 1.03). Glioblastoma demonstrated a higher incidence risk (HR per 5 kg/m, 1.02; 95% CI 1.00 to 1.05) and better survival outcomes (HR 0.75; 95% CI 0.59 to 0.96) with increasing BMI.
This study provides critical insights into the relationship between glioma and anthropometric measures. Glioma and glioblastoma were associated with these measures in terms of both incidence and survival. Further research is necessary to uncover the mechanisms and develop preventative or therapeutic strategies.
包括体重指数（BMI）、身高与癌症之间的关联已得到广泛讨论。然而，这些因素在胶质瘤发生发展及预后中的作用仍存在争议。我们旨在研究这些关系。
我们遵循系统评价和Meta分析的首选报告项目（PRISMA）报告指南。报道人体测量指标与胶质瘤风险（包括发病率和生存率）之间关系的论文被视为相关文献。从PubMed、EMBASE和Cochrane图书馆中选取截至2024年1月31日发表的文献。根据改良的纽卡斯尔渥太华量表对研究进行评估。使用随机效应模型汇总并综合风险比、相对风险和95%置信区间。
在筛选的940篇文章中，选取了23篇。身高较高与胶质瘤（每10厘米的风险比，1.19；置信区间，1.16至1.23）和胶质母细胞瘤（每10厘米的风险比，1.25；置信区间，1.18至1.31）风险增加显著相关。较高的BMI与胶质瘤风险增加呈正相关，无论是分类测量（相对风险，1.08；置信区间，1.03至1.12）还是连续测量（每5kg/m²的风险比，1.01；置信区间，1.00至1.03）。随着BMI增加，胶质母细胞瘤表现出更高的发病风险（每5kg/m²的风险比，1.02；95%置信区间1.00至1.05）和更好的生存结果（风险比0.75；95%置信区间0.59至0.96）。
本研究为胶质瘤与人体测量指标之间的关系提供了重要见解。胶质瘤和胶质母细胞瘤在发病率和生存率方面均与这些指标相关。有必要进一步开展研究以揭示其机制并制定预防或治疗策略。
